Johnson & Johnson JNJ

$256.03 -2.63 (-1.02%)

Valuation

Market cap
623,344,192,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.38
Forward PE
22.95
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
10,942,100
Avg volume
6,722,124
Day's range
$255.12 – $259.38
Shares out
2,409,898,000
Stochastic %K
5%
Beta
0.21
Analysts
Strong Sell
Price target
$282.28

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Outcomes Oct 2, 11:03 PM
$IBRX $MRNA $MRK $PFE $JNJ …..tip of the iceberg https://open.substack.com/pub/aaronsiri/p/recap-of-some-of-the-lawsuits-petitions?r=re3i2&utm_medium=ios
1 replies
Outcomes Oct 2, 8:43 PM
$IBRX $MRNA $MRK $PFE $JNJ ....'gene therapy'...hard pass. mRNA BAD. I'll prefer ANKTIVA please, thank you. https://x.com/robinmonotti/status/2090353470247202938?s=20
2 replies
SellasgpsCurativeBAT11 Oct 2, 6:00 PM
$JNJ $SLS lot of people here don't know this but Sellas BOD Bach and Johnson & Johnson VP Cavanaugh were a team that facilitated one of the biggest deal in biotechnology in past Decade. Katherine Bach Kalin is connected to Tom Cavanaugh through their extensive executive ties in the biopharmaceutical industry, most notably their history at Celgene. Both Kalin and Cavanaugh served simultaneously as senior executives at Celgene between 2012 and 2017, where they worked closely on global corporate strategy, commercial planning, and product development. During or building from their tenures, Celgene was acquired by Bristol-Myers Squibb (BMS) in a massive $74 billion mega-merger, a transaction that heavily featured the immunotherapy portfolios both executives managed. Kalin spent nearly a decade at Johnson & Johnson (J&J) early in her career (2002-2011). Tom Cavanaugh was later appointed as J&J's Executive Vice President and Worldwide Chairman of Innovative Medicine ! ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Oct 2, 5:57 PM
$SLS $JNJ My money is all on $JNJ picking up Sellas via Outright BO very soon. now-deleted Linkedin comment allegedly written by a J&J product director. In the comment, the individual allegedly praised Sellas' lead immunotherapy asset, Galinpepimut-S (GPS), and its Phase 3 REGAL trial, calling it a "game changer for AML (acute myeloid leukemia) care." Context & Takeover Speculation The deleted post significantly fueled retail market speculation regarding a potential buyout or strategic partnership between J&J and Sellas. This buzz was driven by several overlapping factors at the time: ® • Oncology Push: Johnson & Johnson had publicly stated its goal to become the world's No. 1 oncology company by 2030, actively searching for cancer-drug acquisitions. • Corporate Ties: On the r/sellaslifesciences Reddit community, users pointed out existing connections, noting that Sellas board member Katherine Bach Kalin was a former long-time J&J executive. Exciting times coming up! ✌️🙏❤️‍🩹
1 replies
SparkyReturns Oct 2, 2:34 PM
$ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $IBRX $JNJ $MRK $BAX
3 replies
pilobious Oct 2, 1:51 PM
$ALNY $VRTX $INCY $JNJ …. I didn’t get the message to sell all my biotech. I really need better news.
1 replies
tonyp262 Oct 2, 1:32 PM
$JNJ this just doesn’t care anymore. Market is up. Good news on the ticker. Still down on the day.
1 replies
tommy45 Oct 2, 1:11 PM
$JNJ buying some calls for next week here gl
0 replies